Prof. Hiddo Heerspink: Insights from DAPA-CKD
- Author
- Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
- Published
- Tue 01 Sep 2020
- Episode Link
- https://audioboom.com/posts/7672328
In this special edition episode of the Endocrine Outlook, you will hear from Professor Hiddo Heerspink.
Heerspink recently presented results of the DAPA-CKD trial at the European Society of Cardiology examining the effects of dapagliflozin (Farxiga) in patients with chronic kidney disease with and without type 2 diabetes. This episode further explores the study and how its results inform the use of dapagliflozin in patients with and without type 2 diabetes.
